Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial

ObjectiveApatinib and irinotecan are used as systematic therapies for advanced gastric adenocarcinoma (GAC) and gastroesophageal junction adenocarcinoma (GEJA), while the evidence for their combination as second-line therapy in these patients is limited. This study aimed to evaluate the efficacy and...

Full description

Bibliographic Details
Main Authors: Jinglei Qu, Xin He, Ying Luo, Ping Yu, Ying Chen, Jing Liu, Xin Wang, Chang Wang, Tingting Liang, Yuxian Bai, Yu Han, Li Man, Chuanchun Leng, Caiyun Zhou, Lijie He, Yunpeng Liu, Xiujuan Qu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
second-line apatinib plus irinotecan
gastric adenocarcinoma
gastroesophageal junction adenocarcinoma
treatment efficacy
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1072943/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1072943/full

Similar Items